
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros is a leader in innovative biotechnology, with a strong portfolio of clinical-stage development programs targeting a variety of diseases, and has shown strong early success in its commercial launch of YARTEMLEA for TA-TMA. Additionally, with promising pipeline candidates such as OMS1029, OMS527, and OncotoX-AML, as well as a strong balance sheet, Omeros has a positive outlook for continued growth and earnings potential. The recently announced J-code for YARTEMLEA should also improve reimbursement clarity and potentially accelerate uptake of the drug.
Bears say
Omeros is facing reimbursement friction and a lack of standardized claims processing due to the newly approved TA-TMA drug YARTEMLEA, which may negatively impact its commercial potential. Additionally, the company has a relatively small cash flow from Omidria royalties. These factors, coupled with the competitive landscape in the biotechnology industry, suggest a negative outlook for Omeros's stock.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares